Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates

3 Mar 2021

Abstract excerpt

Licensed human papillomavirus (HPV) vaccines contain virus-like particles (VLPs) self-assembled from L1 major-capsid proteins that are remarkably effective prophylactic immunogens. However, the induced type-restricted immune response limits coverage to the included vaccine types, and costly multiplex formulations, restrictive storage and distribution conditions drive the need for next generation HPV vaccines....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervical Cancer and HPV Research
Share to Immunotherapy and Immune Responses
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33802456
DOI: 10.3390/jcm10051044

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine CandidatesPMID 33802456Read ↗

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read ↗

Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.Semantic proximity Read ↗

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?Semantic proximity Read ↗

Potential of Recombinant Chimeric HPV16 L1/L2 VLPs Produced by Distinct Cell Lineages Such as Prophylactic Nanovaccine and Therapeutic Drug NanocarriersSemantic proximity Read ↗

RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human CancerSemantic proximity Read ↗

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Semantic proximity Read ↗

L2 epitope presenting virus-like particles as broad- spectrum vaccine candidates targeting genus beta human papillomavirusesSemantic proximity Read ↗

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2Semantic proximity Read ↗

In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccineSemantic proximity Read ↗

A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2Semantic proximity Read ↗

Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like ParticlesSemantic proximity Read ↗

Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and ImmunogenicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.